News from Zyme and the companies we work with.
Bio-Rad Launches EZ-Check Salmonella spp. Kit for Detection of Salmonella spp. in Food and Environmental Samples
Kit Approved by AOAC International and certified NF VALIDATION by AFNOR Certification HERCULES, Calif. — 19 August Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research [...]
Camena Bioscience and Constructive Bio join synthetic biology collaboration to develop plant genomics
Project backed by £9.1m funding from ARIA, the Advanced Research + Invention Agency, to develop synthetic chloroplast genomes Project is led by the Max-Planck Institute of Molecular Plant Physiology and [...]
Sunil Shah and Dr Catherine Elton join Atelerix’s Board to drive global commercial expansion
Industry leaders Sunil Shah (CEO, o2h Ventures) and Dr Catherine Elton (CBO, Axol Bioscience) appointed as Chair and Non-Executive Director, respectively Newcastle, UK, 12 August 2025: Atelerix, a biotech company [...]
Antibodies.com expands UK headquarters with new 5x larger facilities in Cambridge to accommodate rapid growth
Investment in premises on Cambridge Technopark reflects significant milestone in the Company’s growth Relocation increases logistics and R&D capacity, enabling faster customization and turnaround, strengthening order fulfilment to better support [...]
Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials
CARB-X provides an additional $5.1M to complete the non-clinical safety and efficacy studies with ABX-01 lead candidate Centauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to [...]
Exonate plans ‘CLEAR-DE’ Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema Phase IIb trial to investigate efficacy [...]
PhoreMost appoints Dr Adam Gilbert to Scientific Advisory Board
Expert in targeted protein degradation and drug discovery will support development of the Company’s portfolio of novel small molecule degraders Cambridge, UK, 28 July 2025: PhoreMost Ltd., a next-generation targeted [...]
PhoreMost demonstrates new approach to rationalise molecular glue drug discovery
Breakthrough data validates capabilities of GlueSEEKER platform to identify novel induced protein-protein interactions and expand druggable space Cambridge, UK, 22 July 2025: PhoreMost Ltd., a next-generation targeted protein degradation (TPD) [...]
Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion
Cambridge, UK – 15 July 2025 – Qureight, a techbio company accelerating drug development using its proprietary deep-learning image biomarkers and clinical data analytics platform, today announced the first results [...]
OMED Health Launches New Gastrointestinal Treatments and Services Through Personalized Health Plans
OMED Health Plans build on proprietary OMED Health Breath Analyzer to include clinician-led care pathways, personalized treatments, and clinical consultations Expanded high-value end-to-end solution positions business for rapid growth in [...]
SPT Labtech and Semarion Collaborate to Advance Automated Cell-Based Assay Workflows
Integration of firefly® liquid handling platform and SemaCyte® microcarriers enables flexible, miniaturized, and automated cell assay workflows Cambridge, UK, 9th July 2025: SPT Labtech, a global leader in innovative laboratory [...]
Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer
Experienced clinical immunologist and global life science executive to support progression of lead candidate through the clinic ABX-01 clinical candidate is an immunotherapeutic, based on proprietary Alphamer® platform and designed [...]
